Free Trial
NASDAQ:MIRA

MIRA Pharmaceuticals (MIRA) Stock Price, News & Analysis

MIRA Pharmaceuticals logo
$1.26 -0.14 (-9.96%)
(As of 11/20/2024 ET)

About MIRA Pharmaceuticals Stock (NASDAQ:MIRA)

Key Stats

Today's Range
$1.13
$1.41
50-Day Range
$1.05
$2.20
52-Week Range
$0.51
$5.04
Volume
682,473 shs
Average Volume
3.43 million shs
Market Capitalization
$20.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

MIRA Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
49th Percentile Overall Score

MIRA MarketRank™: 

MIRA Pharmaceuticals scored higher than 49% of companies evaluated by MarketBeat, and ranked 570th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MIRA Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MIRA Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about MIRA Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for MIRA Pharmaceuticals are expected to grow in the coming year, from ($0.60) to ($0.54) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MIRA Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MIRA Pharmaceuticals is -2.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MIRA Pharmaceuticals has a P/B Ratio of 4.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about MIRA Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    12.65% of the float of MIRA Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MIRA Pharmaceuticals has recently increased by 267.78%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    MIRA Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    MIRA Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.65% of the float of MIRA Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    MIRA Pharmaceuticals has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MIRA Pharmaceuticals has recently increased by 267.78%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    MIRA Pharmaceuticals has a news sentiment score of 1.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.
  • Search Interest

    21 people have searched for MIRA on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added MIRA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MIRA Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.65% of the stock of MIRA Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 35.16% of the stock of MIRA Pharmaceuticals is held by institutions.

  • Read more about MIRA Pharmaceuticals' insider trading history.
Receive MIRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MIRA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MIRA Stock News Headlines

MIRA Continues Solid Financial Management
Mira Pharmaceuticals announces preclinical data on Ketamir-2
Tesla Execs are Freaking Out
It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.
MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments
See More Headlines

MIRA Stock Analysis - Frequently Asked Questions

MIRA Pharmaceuticals' stock was trading at $1.05 at the start of the year. Since then, MIRA shares have increased by 20.5% and is now trading at $1.2650.
View the best growth stocks for 2024 here
.

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) posted its earnings results on Tuesday, November, 12th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.04.

MIRA Pharmaceuticals (MIRA) raised $9 million in an initial public offering (IPO) on Thursday, August 3rd 2023. The company issued 1,275,000 shares at a price of $7.00 per share.

Top institutional investors of MIRA Pharmaceuticals include Cross Staff Investments Inc (2.48%) and Suncoast Equity Management (0.61%). Insiders that own company stock include George Cappy, Brian Patrick Mcnulty and Erez Aminov.
View institutional ownership trends
.

Shares of MIRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that MIRA Pharmaceuticals investors own include Plug Power (PLUG), Workhorse Group (WKHS), FuelCell Energy (FCEL), Fortress Biotech (FBIO), Ovid Therapeutics (OVID), Alamos Gold (AGI) and GeoVax Labs (GOVX).

Company Calendar

Last Earnings
11/12/2024
Today
11/20/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
4/07/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MIRA
Previous Symbol
NASDAQ:MIRA
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$17.00
Low Stock Price Target
$11.00
Potential Upside/Downside
+1,006.7%
Consensus Rating
Buy
Rating Score (0-4)
3.33
Research Coverage
3 Analysts

Profitability

Net Income
$-11,980,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.30 per share

Miscellaneous

Free Float
15,460,000
Market Cap
$20.95 million
Optionable
Not Optionable
Beta
3.09
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:MIRA) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners